Pliant Therapeutics, Inc.

Informe acción NasdaqGS:PLRX

Capitalización de mercado: US$74.3m

Pliant Therapeutics Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Bernard Coulie

Chief Executive Officer (CEO)

US$5.5m

Compensación total

Porcentaje del salario del CEO12.48%
Permanencia del CEO10.3yrs
Participación del CEO1.2%
Permanencia media de la dirección2.3yrs
Promedio de permanencia en la Junta Directiva6.4yrs

Actualizaciones recientes de la dirección

Recent updates

Seeking Alpha • Feb 24

Pliant Therapeutics: A Reverse Arbitrage Opportunity Driven By A Poison Pill Expiration

Summary Pliant Therapeutics trades at a deep discount to net cash after Bexotegrast's Phase 3 failure, with a $70M market cap versus $186M cash. Activist Kevin Tang holds 9.6%; given the 85%+ institutional base, the March 2026 poison pill expiration signals a potential liquidation or premium buyout. PLRX's cash burn has been slashed, extending runway to 2028, but continued independent operation is untenable; forced liquidation or cash privatization is highly likely in my opinion. I exploit negative EV and high implied volatility by selling cash-secured $1.00 puts expiring July 2026, targeting a >50% annualized return with limited downside. Read the full article on Seeking Alpha
Seeking Alpha • Feb 11

Pliant Therapeutics: Strange Volatility

Summary Pliant Therapeutics paused its phase 2b/3 trial of bexotegrast for idiopathic pulmonary fibrosis due to DSMB recommendations, causing significant stock volatility. High trading volumes and sharp stock declines occurred before the announcement, indicating potential insider activity, making PLRX highly risky for retail investors. The DSMB's rationale for pausing the trial remains unclear, with no major safety issues previously reported, adding to the uncertainty. PLRX has a cash runway of 5–6 quarters, but faces risks due to volatile stock movements and confusing trial data; I recommend avoiding PLRX. Read the full article on Seeking Alpha
Artículo de análisis • Jan 02

Pliant Therapeutics (NASDAQ:PLRX) Has Debt But No Earnings; Should You Worry?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Artículo de análisis • Sep 13

Is Pliant Therapeutics (NASDAQ:PLRX) Using Too Much Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Seeking Alpha • Sep 11

Pliant Therapeutics: Good Data, But Will Need Watching

Summary Pliant Therapeutics' stock initially surged, but has since fallen due to mixed trial results and competitive pressures. Bexotegrast showed promising results in IPF and PSC trials, but dose-response inconsistencies and competition raise concerns. Despite positive data, the stock's decline suggests market skepticism, further exacerbated by Novartis ending a partnership. With a cash runway of 5-6 quarters, PLRX needs clarity on regulatory plans and later-stage trial data before making investment decisions. Read the full article on Seeking Alpha
Artículo de análisis • Jun 07

Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?

Key Insights Pliant Therapeutics' Annual General Meeting to take place on 13th of June CEO Bernard Coulie's total...
Artículo de análisis • Feb 27

Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Artículo de análisis • Jul 21

Is Pliant Therapeutics (NASDAQ:PLRX) Using Debt Sensibly?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Artículo de análisis • Mar 13

Health Check: How Prudently Does Pliant Therapeutics (NASDAQ:PLRX) Use Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Artículo de análisis • Sep 10

Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Seeking Alpha • Aug 20

Pliant Therapeutics: Wait For A Better Price To Get In

PLRX went up 200% on strong phase 2a data in IPF. Even a subsequent large dilution was unable to dampen enthusiasm. A better, more derisked price after next year's 320mg data drop will be a good time to buy in. I wrote about a small company named Pliant Therapeutics (PLRX) two years ago. Pliant interested me because despite being an under-the-radar company, it had important collaborations, and it worked in fibrotic diseases. In July, Pliant stock went up after data from a phase 2a trial - designed to test safety and tolerability - also showed the drug’s efficacy in improving forced vital capacity or FVC in idiopathic pulmonary fibrosis patients. Although a trial of only 12 weeks may not be enough to convince scientists, and while there was confusion about dose dependent improvements because a smaller dose showed better efficacy than a higher one, Pliant stock has been on the rise. Data from a higher dosage cohort, coming next year, will help remove the confusion. Interestingly, Pliant’s own CEO once doubted that such a small trial will show FVC improvements. Pliant works in integrin-mediated inhibition of the TGF-β pathway, which reduces fibrosis and is safe. The science is described thus in the 10-K: We believe that tissue-specific inhibition of TGF-β may hold the key to successfully treating fibrosis. In normal tissues, TGF-β is activated in response to tissue injury which initiates a cascade that results in collagen production and, ultimately, scar formation to heal the tissue. In fibrosis, however, TGF-β signaling becomes dysregulated, with TGF-β being continuously activated, leading to excess collagen deposition, even in the absence of acute tissue injury. TGF-β, while implicated in fibrosis pathophysiology, is expressed, and intermittently activated across all tissue types and plays important, contextspecific roles in tissue homeostasis. Therefore, TGF-β cannot be blocked systemically without disrupting these homeostatic functions and causing significant toxicities. To treat fibrosis more precisely in specific tissues, we believe it is crucial to discover and treat the underlying mechanism causing excess TGF-β activation. Our scientific founders are pioneers in elucidating the role of specific extracellular receptors known as integrins as a key element in the activation of TGF-β. The company is running trials in Idiopathic Pulmonary Fibrosis or IPF and Primary Sclerosing Cholangitis or PSC. The product candidate is called PLN-74809. These are ongoing phase 2a trials with data to topline next year. Another candidate, PLN-1474, is being developed for NASH-Associated Liver Fibrosis in collaboration with Novartis (NVS). This year, the company announced data from a proof of concept trial. From the 10-K: In February 2022, we announced positive results from an expanded PLN-74809 Phase 1b proof-of-mechanism trial. This study evaluated PLN74809's ability to suppress TGF-β activation in the lungs of healthy volunteers as measured through relative pSmad2 levels in alveolar macrophages collected through bronchioalveolar lavage ((BAL)) at 6 hours and 24 hours after the last dose. The trial was conducted in two parts. Part 1 evaluated PLN-74809 at doses of 80 mg and 160 mg versus placebo and Part 2 evaluated PLN-74809 at 320 mg versus placebo. PLN-74809 demonstrated clear evidence of on-target biological activity in the lungs of healthy participants. Results showed that PLN-74809 inhibited TGF-β activation by up to 92% and 76% at 6- and 24-hours, respectively, following dosing. PLN-74809 was well tolerated with mostly mild adverse events, and no severe adverse events. There was no dose relationship associated with adverse events, no serious adverse events (SAEs) and no treatment discontinuations due to adverse events. This trial further defines the relationship between plasma exposure of PLN-74809 and TGF-β inhibition in the lung and will guide dose selection in future trials.
Seeking Alpha • Aug 08

Pliant Therapeutics GAAP EPS of -$0.82 misses by $0.01, revenue of $4.99M

Pliant Therapeutics press release (NASDAQ:PLRX): Q2 GAAP EPS of -$0.82 misses by $0.01. Revenue of $4.99M (+178.8% Y/Y).
Artículo de análisis • Jul 28

Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jul 21

Pliant's PLN-74809 gets FDA fast track status for liver disease

The U.S. Food and Drug Administration (FDA) granted fast track designation to Pliant Therapeutics' (NASDAQ:PLRX) PLN-74809 to treat primary sclerosing cholangitis (PSC). PSC is a chronic liver disease in which the bile ducts — which carry the digestive fluid from the liver to the small intestine — become inflamed and scarred causing them to become hard and narrow leading to liver damage. People with PSC may also also have inflammatory bowel disease. The company said PLN-74809 is currently being tested as part of a phase 2a trial called  INTEGRIS-PSC, data from which is expected in H1 2023. PLRX +2.44% to $20.17 premarket July 21
Seeking Alpha • Jul 11

Pliant climbs 48% as mid-stage trial for lung disease therapy meets key goals

The shares of clinical-stage biopharma Pliant Therapeutics (NASDAQ:PLRX) gained ~48% in the pre-market Monday after the company announced its mid-stage trial for PLN-74809 in idiopathic pulmonary fibrosis (IPF) reached key goals. The 90-patient Phase 2a multinational study met its primary and secondary endpoints indicating that the study drug was well tolerated over 12 weeks of treatment with a favorable pharmacokinetic profile, the company said. According to data, PLN-74809 demonstrated dose-dependent effects on forced vital capacity (FVC) and Quantitative Lung Fibrosis (QLF) imaging compared to placebo over 12 weeks. The drug was found to be safe across all three doses of 40 mg, 80 mg, and 160 mg, with 97% in the 67-patient active arm completing the treatment with no discontinuations due to adverse events, according to Pliant (PLRX). In the near-term, the company plans to submit the data to regulators targeting the late-stage development of PLN-74809. According to Seeking Alpha contributor Terry Chrisomalis, a major catalyst awaits Pliant (PLRX) investors in early next year.
Seeking Alpha • Jun 03

Pliant: Major Catalyst Expected Beginning Of 2023

Results from the phase 2a INTEGRIS-PSC study using PLN-74809 for the treatment of patients with primary sclerosing cholangitis are expected 1st half of 2023. PLN-74809 is also being explored for the treatment of patients with idiopathic pulmonary fibrosis; Preliminary safety and efficacy data was released in 5 poster presentations at medical conference. The global idiopathic pulmonary fibrosis market is expected to reach $4.7 billion by 2027. Other indications in the pipeline include NASH fibrosis, Oncology targets and muscular dystrophy as well which de-risk the pipeline.

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Bernard Coulie en comparación con los beneficios de Pliant Therapeutics?
FechaCompensación totalSalarioIngresos de la empresa
Mar 31 2026n/an/a

-US$113m

Dec 31 2025US$5mUS$682k

-US$149m

Sep 30 2025n/an/a

-US$175m

Jun 30 2025n/an/a

-US$207m

Mar 31 2025n/an/a

-US$220m

Dec 31 2024US$7mUS$641k

-US$210m

Sep 30 2024n/an/a

-US$202m

Jun 30 2024n/an/a

-US$185m

Mar 31 2024n/an/a

-US$171m

Dec 31 2023US$11mUS$610k

-US$161m

Sep 30 2023n/an/a

-US$155m

Jun 30 2023n/an/a

-US$144m

Mar 31 2023n/an/a

-US$133m

Dec 31 2022US$11mUS$587k

-US$123m

Sep 30 2022n/an/a

-US$113m

Jun 30 2022n/an/a

-US$109m

Mar 31 2022n/an/a

-US$103m

Dec 31 2021US$5mUS$556k

-US$97m

Sep 30 2021n/an/a

-US$92m

Jun 30 2021n/an/a

-US$81m

Mar 31 2021n/an/a

-US$75m

Dec 31 2020US$2mUS$499k

-US$42m

Sep 30 2020n/an/a

US$18m

Jun 30 2020n/an/a

US$19m

Mar 31 2020n/an/a

US$20m

Dec 31 2019US$2mUS$428k

-US$7m

Compensación vs. Mercado: La compensación total de Bernard($USD5.46M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD638.05K).

Compensación vs. Ingresos: La compensación de Bernard ha sido consistente con los resultados de la empresa en el último año.

CEO

Bernard Coulie (59 yo)

10.3yrs
Permanencia
US$5,462,901
Compensación

Dr. Bernard Coulie is Independent Director of Biogazelle NV. Dr. Coulie is Independent Director of Septerna, Inc. from December 2023. He served as Independent Director at SQZ Biotechnologies Company since...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Bernard Coulie
Presidentno dataUS$5.46m1.23%
$ 916.6k
Keith Cummings
Chief Financial Officer7.4yrsUS$2.40m0.39%
$ 289.2k
Minnie Kuo
Chief Operating Officerless than a yearUS$1.54m0.061%
$ 45.4k
Rik Derynck
Scientific Founder & Member of Scientific Advisory Board11.3yrssin datossin datos
Dean Sheppard
Scientific Founder & Member of Scientific Advisory Board11.3yrssin datossin datos
Hal Chapman
Scientific Founder & Member of Scientific Advisory Board11.3yrssin datossin datos
Delphine Imbert
Chief Technical Officer1.3yrssin datossin datos
Christopher Keenan
Vice President of Investor Relations & Corporate Communicationsno datasin datossin datos
Monica Sandberg
Vice Presidentless than a yearsin datossin datos
Lily Cheung
Chief Human Resources Officer3.3yrssin datos0.031%
$ 22.7k
Tim Machajewski
Senior VP & Head of Research1.3yrssin datossin datos
Scott Peters
Senior Vice President of Financeless than a yearsin datossin datos
2.3yrs
Permanencia media
49.5yo
Promedio de edad

Equipo directivo experimentado: El equipo directivo de PLRX se considera experimentado (2.3 años antigüedad media).

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Bernard Coulie
President10.3yrsUS$5.46m1.23%
$ 916.6k
Rik Derynck
Scientific Founder & Member of Scientific Advisory Boardno datasin datossin datos
Dean Sheppard
Scientific Founder & Member of Scientific Advisory Boardno datasin datossin datos
Hal Chapman
Scientific Founder & Member of Scientific Advisory Boardno datasin datossin datos
Gayle Crowell
Independent Director6.4yrsUS$95.10k0%
$ 0
David E. Pyott
Independent Director5.3yrsUS$90.10k0%
$ 0
Suzanne Bruhn
Independent Director9.8yrsUS$87.60k0.057%
$ 42.1k
John Curnutte
Independent Director8.8yrsUS$82.60k0.047%
$ 35.1k
Hoyoung Huh
Independent Chairman & Lead Director8.4yrsUS$112.60k0.16%
$ 119.7k
Steve Krognes
Independent Director1.9yrsUS$95.10k0%
$ 0
Darren Cline
Independent Director3.2yrsUS$90.10k0%
$ 0
Katharine Knobil
Independent Director3.7yrsUS$95.10k0%
$ 0
6.4yrs
Permanencia media
61yo
Promedio de edad

Junta con experiencia: La junta directiva de PLRX se considera experimentada (6.4 años de antigüedad promedio).

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/05/21 17:58
Precio de las acciones al final del día2026/05/21 00:00
Beneficios2026/03/31
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Pliant Therapeutics, Inc. está cubierta por 13 analistas. 6 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Edward NashCanaccord Genuity
David LebowitzCitigroup Inc
Lut Ming ChengJ.P. Morgan